TRAFD1

Across TCGA pan-cancer cohorts, TRAFD1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAFD1 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TRAFD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TRAFD1 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where TRAFD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.311	0.579	.023	14	view →
HNSC	OS	Quartile	III,IV	0.720	0.963	.008	8	view →
LUAD	OS	Median	III,IV	1.000	0.663	.007	8	view →
COAD	DFS	Quartile	All	0.900	1.000	.042	6	view →
CCRCC	OS	Median	All	0.647	1.000	.005	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAFD1–PDAC (OS)

Open the PDAC breakdown →